课题基金 / 基金详情

: A Phase Ib Biomarker Trial of Naproxen in Patients at Risk for DNA Mismatch

: A Phase Ib Biomarker Trial of Naproxen in Patients at Risk for DNA Mismatch
:对有 DNA 错配风险的患者进行萘普生 Ib 期生物标志物试验
批准号:
8762954
负责人:
TERISA DAVIS
金额:
$105.08万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-20 至 2017-09-19

项目摘要

项目成果

TERISA DAVIS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The proposed trial shall address whether Naproxen, a nonsteroidal anti-inflammatory agent in widespread clinical use primarily for the treatment of pain and inflammation, can safely and effectively be given in a once daily dose to subjects at risk for a mismatch repair deficient colon carcinoma, and how and whether it modulates a series of biomarkers and other parameters in this specific population. The trial shall be performed at the MD Anderson Cancer Center, the Dana Farber Cancer Center and the University of Michigan. All three institutions shall participate in the various aspects of the trial.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SCIENTIFIC SUPPORT SERVICES FOR THE NATIONAL CANCER INSTITUTE, DIVISIOIN OF CANCER CONTROL AND POPULATION SCIENCES (DCCPS)
  • 批准号:
    10458431
  • 项目类别:
  • 资助金额:
    $222.97万
  • 财政年份:
    2020
  • 负责人:
    TERISA DAVIS
  • 依托单位:
SCIENTIFIC SUPPORT SERVICES FOR THE NATIONAL CANCER INSTITUTE, DIVISIOIN OF CANCER CONTROL AND POPULATION SCIENCES (DCCPS)
  • 批准号:
    10225274
  • 项目类别:
  • 资助金额:
    $277.91万
  • 财政年份:
    2020
  • 负责人:
    TERISA DAVIS
  • 依托单位:
SCIENTIFIC SUPPORT SERVICES FOR THE NATIONAL CANCER INSTITUTE, DIVISIOIN OF CANCER CONTROL AND POPULATION SCIENCES (DCCPS)
  • 批准号:
    10671441
  • 项目类别:
  • 资助金额:
    $269.22万
  • 财政年份:
    2020
  • 负责人:
    TERISA DAVIS
  • 依托单位:
Scientific Support Services for the National Cancer Institute, Division of Cancer Control and Population Sciences (DCCPS). POP 7/27/2019 - 7/26/2020.
  • 批准号:
    10039262
  • 项目类别:
  • 资助金额:
    $280.6万
  • 财政年份:
    2019
  • 负责人:
    TERISA DAVIS
  • 依托单位:
海外基金